share_log

While Private Companies Own 32% of Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262), Individual Investors Are Its Largest Shareholders With 32% Ownership

While Private Companies Own 32% of Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262), Individual Investors Are Its Largest Shareholders With 32% Ownership

尽管私营公司拥有恩华药业股份有限公司(SZSE:002262)32%的股份,但个人投资者是其最大的股东,拥有32%的股份
Simply Wall St ·  09/04 18:12

Key Insights

关键见解

  • Jiangsu Nhwa Pharmaceutical's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public
  • 51% of the business is held by the top 6 shareholders
  • Insider ownership in Jiangsu Nhwa Pharmaceutical is 18%
  • 江苏恩华药业拥有大量个人投资者的所有权,这表明关键决策受广大公众股东的影响
  • 51% 的业务由前6名股东持有
  • 江苏恩华药业的内部所有权为18%

If you want to know who really controls Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 32% to be precise, is individual investors. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

如果你想知道谁真正控制着江苏恩华药业股份有限公司(SZSE:002262),那么你必须看看其股票登记处的构成。持有公司股份最多的集团是个人投资者,准确地说约为32%。换句话说,该集团将从对公司的投资中获得最多(或损失最大)。

And private companies on the other hand have a 32% ownership in the company.

另一方面,私营公司拥有该公司32%的所有权。

In the chart below, we zoom in on the different ownership groups of Jiangsu Nhwa Pharmaceutical.

在下图中,我们放大了江苏恩华制药的不同所有权群体。

big
SZSE:002262 Ownership Breakdown September 4th 2024
SZSE: 002262 所有权明细 2024 年 9 月 4 日

What Does The Institutional Ownership Tell Us About Jiangsu Nhwa Pharmaceutical?

关于江苏恩华制药,机构所有权告诉我们什么?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

机构在向自己的投资者报告时通常会根据基准来衡量自己,因此,一旦股票被纳入主要指数,他们通常会对股票更加热情。我们预计大多数公司都会有一些机构在册,尤其是在它们正在成长的情况下。

As you can see, institutional investors have a fair amount of stake in Jiangsu Nhwa Pharmaceutical. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Jiangsu Nhwa Pharmaceutical's historic earnings and revenue below, but keep in mind there's always more to the story.

如你所见,机构投资者持有江苏恩华制药的相当数量的股份。这表明专业投资者有一定的信誉。但是我们不能仅仅依靠这个事实,因为机构有时会像所有人一样进行不良投资。当多家机构拥有一只股票时,总是存在处于 “拥挤交易” 的风险。当这样的交易出错时,多方可能会竞相快速出售股票。对于没有增长历史的公司,这种风险更高。你可以在下面看到江苏恩华制药的历史收益和收入,但请记住,故事总是有更多内容。

big
SZSE:002262 Earnings and Revenue Growth September 4th 2024
SZSE: 002262 2024 年 9 月 4 日收益和收入增长

Jiangsu Nhwa Pharmaceutical is not owned by hedge funds. Xuzhou Nhwa Investment Co., Ltd. is currently the largest shareholder, with 32% of shares outstanding. In comparison, the second and third largest shareholders hold about 4.9% and 3.9% of the stock. Zengliang Chen, who is the third-largest shareholder, also happens to hold the title of Member of the Board of Directors.

江苏恩华药业不归对冲基金所有。徐州恩华投资有限公司目前是最大股东,已发行股份的32%。相比之下,第二和第三大股东持有约4.9%和3.9%的股份。第三大股东陈增亮也恰好拥有董事会成员的头衔。

On further inspection, we found that more than half the company's shares are owned by the top 6 shareholders, suggesting that the interests of the larger shareholders are balanced out to an extent by the smaller ones.

经过进一步检查,我们发现公司一半以上的股份由前六名股东持有,这表明较大股东的利益在一定程度上被较小的股东所平衡。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

研究机构所有权是衡量和筛选股票预期表现的好方法。通过研究分析师的情绪也可以达到同样的目的。有相当数量的分析师在报道该股,因此了解他们对未来的总体看法可能很有用。

Insider Ownership Of Jiangsu Nhwa Pharmaceutical

江苏恩华药业的内部所有权

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

不同国家对内部人士的定义可能略有不同,但董事会成员总是计算在内。公司管理层对董事会的回答,董事会应代表股东的利益。值得注意的是,有时高层管理人员自己也在董事会中。

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

当内部所有权表明领导层像公司的真正所有者一样思考时,内部所有权是积极的。但是,高度的内部所有权也可以赋予公司内部的一小部分人巨大的权力。在某些情况下,这可能是负面的。

Our most recent data indicates that insiders own a reasonable proportion of Jiangsu Nhwa Pharmaceutical Co., LTD. It has a market capitalization of just CN¥27b, and insiders have CN¥4.7b worth of shares in their own names. That's quite significant. Most would be pleased to see the board is investing alongside them. You may wish to access this free chart showing recent trading by insiders.

我们最新的数据表明,内部人士拥有江苏恩华药业股份有限公司合理比例的股份。它的市值仅为270元人民币,内部人士以自己的名义持有价值47元人民币的股票。这非常重要。大多数人会很高兴看到董事会与他们一起投资。您不妨访问这张显示内部人士近期交易的免费图表。

General Public Ownership

一般公有制

The general public, who are usually individual investors, hold a 32% stake in Jiangsu Nhwa Pharmaceutical. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

公众通常是个人投资者,持有江苏恩华制药32%的股份。这种所有权规模虽然可观,但如果决策与其他大股东不同步,可能不足以改变公司政策。

Private Company Ownership

私人公司所有权

It seems that Private Companies own 32%, of the Jiangsu Nhwa Pharmaceutical stock. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

私人公司似乎拥有江苏恩华制药32%的股份。仅凭这一事实很难得出任何结论,因此值得研究谁拥有这些私营公司。有时,内部人士或其他关联方通过一家独立的私人公司对上市公司的股份拥有权益。

Next Steps:

后续步骤:

It's always worth thinking about the different groups who own shares in a company. But to understand Jiangsu Nhwa Pharmaceutical better, we need to consider many other factors.

拥有公司股份的不同群体总是值得考虑的。但是,要更好地了解江苏恩华制药,我们需要考虑许多其他因素。

I like to dive deeper into how a company has performed in the past. You can find historic revenue and earnings in this detailed graph.

我喜欢更深入地了解一家公司过去的表现。您可以在这张详细图表中找到历史收入和收入。

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

如果你像我一样,你可能需要考虑这家公司是会成长还是会萎缩。幸运的是,您可以查看这份免费报告,其中显示了分析师对其未来的预测。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧吗?请直接联系我们。或者,也可以发送电子邮件至编辑团队 (at) simplywallst.com。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发